Efficacy and safety of baricitinib in patients with refractory alopecia areata

Dermatol Ther. 2022 Dec;35(12):e15845. doi: 10.1111/dth.15845. Epub 2022 Oct 18.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Alopecia Areata* / drug therapy
  • Azetidines* / adverse effects
  • Humans
  • Purines / adverse effects

Substances

  • baricitinib
  • Azetidines
  • Purines

Supplementary concepts

  • Diffuse alopecia